NasdaqCM - Nasdaq Real Time Price USD

enVVeno Medical Corporation (NVNO)

Compare

2.3800

+0.0400

+(1.71%)

At close: 4:00:01 PM EDT

2.3800

0.00

(0.00%)

After hours: 4:05:06 PM EDT

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

Moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Tuesday, April 22nd at 4:00 PM ET IRVINE, CA / ACCESS Newswire / April 16, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company ...

ACCESS Newswire 9 hours ago

NVNBW

NVNO
+1.71%
NVNOW
The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

IRVINE, CA / ACCESS Newswire / March 31, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced its abstract has been accepted for ...

ACCESS Newswire 16 days ago

NVNBW

NVNO
+1.71%
NVNOW
enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

Cash Burn of $5.2 million in Q4 remains in line with projected $4-5 million quarterly range Cash and investments on hand are sufficient to fund operations beyond the anticipated regulatory approval of VenoValve and the initiation of the enVVe pivotal ...

ACCESS Newswire last month

NVNBW

NVNO
+1.71%
NVNOW
enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available here IRVINE, CA / ACCESS Newswire / February 19, 2025 /enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today ...

ACCESS Newswire last month

NVNBW

NVNO
+1.71%
NVNOW
One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

One-year follow-up data demonstrates sustained improvements across venous specific quality-of-life (QoL) indicators. PMA application for the VenoValve submitted in November 2024, with an FDA decision expected in the second half of 2025. IRVINE, CA ...

ACCESS Newswire last month

NVNBW

NVNO
+1.71%
NVNOW
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months. 78% of subjects maintained a clinically meaningful benefit of more than 3 points ...

ACCESS Newswire 2 months ago

NVNBW

NVNO
+1.71%
NVNOW
Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 2 months ago

NVNBW

NVNO
+1.71%
NVNOW
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the successful completion of the final wave of implants for shorter-term subjects ...

ACCESS Newswire 3 months ago

NVNBW

NVNO
+1.71%
NVNOW
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

Interviews with participating patients from the VenoValve® U.S. Pivotal Trial Webcast replay from with the presenting Primary Investigators Presentation with data from the VenoValve U.S. Pivotal Trial Access the Recap Website Here! IRVINE, CA / ACCESSWIRE ...

ACCESS Newswire 4 months ago

NVNBW

NVNO
+1.71%
NVNOW
enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, will present one year data on all subjects from the VenoValve U.S. pivotal trial today at the 51st ...

ACCESS Newswire 4 months ago

NVNBW

NVNO
+1.71%
NVNOW
enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it has submitted its application with the U.S. Food and Drug Administration (FDA) ...

ACCESS Newswire 4 months ago

NVNBW

NVNO
+1.71%
NVNOW
enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year

Continued progress toward submission of 5th and final module of FDA premarket approval (PMA) application for VenoValve® in Q4 GLP study for enVVe® transcatheter-based replacement venous valve underway; On track to file IDE approval for pivotal trial ...

ACCESS Newswire 5 months ago

NVNBW

NVNO
+1.71%
NVNOW
enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)

First wave of implants successfully completed with updated delivery system performing very well Company on schedule to be in position to apply for approval for enVVe pivotal trial mid-2025 IRVINE, CA / ACCESSWIRE / October 28, 2024 / enVVeno Medical ...

ACCESS Newswire 5 months ago

NVNBW

NVNO
+1.71%
NVNOW
enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering

IRVINE, CA / ACCESSWIRE / September 26, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the pricing of an underwritten public ...

ACCESS Newswire 6 months ago

NVNBW

NVNO
+1.71%
NVNOW
enVVeno Medical Corporation Announces Proposed Public Offering

IRVINE, CA / ACCESSWIRE / September 26, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that it is proposing to offer and sell, ...

ACCESS Newswire 6 months ago

NVNBW

NVNO
+1.71%
NVNOW
enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing

MedTech Marketing Leader with Significant New Product Launch Experience for Cardiovascular Devices Key Addition to Commercial Team as Company Begins Planning for the VenoValve Monetization Several Upcoming Company Milestones Planned for Q4 of 2024 ...

ACCESS Newswire 7 months ago

NVNBW

NVNO
+1.71%
NVNOW
enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R)

VenoValve PMA Approval Application Process Consists of the Submission of 5 Modules to the FDA 4 Modules Have Now Been Submitted, Reviewed, and Approved by the FDA Company on Track to File the 5th and Final Module in Q4 2024 IRVINE, CA / ACCESSWIRE ...

ACCESS Newswire 7 months ago

NVNBW

NVNO
+1.71%
NVNOW
Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Simply Wall St. 8 months ago

NVNBW

NVNO
+1.71%
NVNOW
enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update

- Ended the quarter with $39.1 million cash and investments on hand sufficient to fund operations, through the end of 2025, including potential PMA approval of VenoValve® - Positive interim venous ulcer healing data showing significant improvement ...

ACCESS Newswire 8 months ago

NVNBW

NVNO
+1.71%
NVNOW
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Thursday, June 27th at 4:00 PM ET IRVINE, CA / ACCESSWIRE / June 25, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting ...

ACCESS Newswire 9 months ago

NVNBW

NVNO
+1.71%
NVNOW

Performance Overview

Return	NVNO	S&P 500 (^GSPC)
YTD	-21.19%	-10.30%
1-Year	-50.00%	+4.44%
3-Year	-56.04%	+20.10%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

enVVeno Medical Corporation (NVNO)

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year

enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)

enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering

enVVeno Medical Corporation Announces Proposed Public Offering

enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing

enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R)

Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation

enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

Performance Overview